Enzootic bovine leucosis (EBL) has been assessed according to the criteria of the Animal Health Law (AHL), in particular criteria of Article 7 on disease profile and impacts, Article 5 on the eligibility of EBL to be listed, Article 9 for the categorisation of EBL according to disease prevention and control rules as in Annex IV and Article 8 on the list of animal species related to EBL. The assessment has been performed following a methodology composed of information collection and compilation, expert judgement on each criterion at individual and, if no consensus was reached before, also at collective level. The output is composed of the categorical answer, and for the questions where no consensus was reached, the different supporting views are reported. Details on the methodology used for this assessment are explained in a separate opinion. According to the assessment performed, it is inconclusive whether EBL can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL because there was no full consensus on the criteria 5 B(i) and 5 B(iii). Consequently, since it is inconclusive whether EBL can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL, then the assessment on compliance of EBL with the criteria as in Sections 4 and 5 of Annex IV to the AHL, for the application of the disease prevention and control rules referred to in points (d) and (e) of Article 9(1), and which animal species can be considered to be listed for EBL according to Article 8(3) of the AHL is also inconclusive.
The background and Terms of Reference (ToR) as provided by the European Commission for the present document are reported in Section 1.2 of the scientific opinion on the ad hoc methodology followed for the assessment of the disease to be listed and categorised according to the criteria of Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA AHAW Panel, 2017).
Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientific opinion on the ad hoc methodology followed for the assessment of the disease to be listed and categorised according to the criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW Panel, 2017) .
The present document reports the results of assessment on enzootic bovine leukosis (EBL) according to the criteria of the AHL articles as follows:
• Article 7: EBL profile and impacts • Article 5: eligibility of EBL to be listed • Article 9: categorisation of EBL according to disease prevention and control rules as in Annex IV • Article 8: list of animal species related to EBL.
Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the ad hoc method developed for assessing any animal disease for the listing and categorisation of diseases within the AHL framework (EFSA AHAW Panel, 2017).
Assessment

Assessment according to Article 7 criteria
This section presents the assessment of EBL according to the Article 7 criteria of the AHL and related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on the information contained in the fact-sheet as drafted by the selected disease scientist (see Section 2.1 of the scientific opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Profile 3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 -Naturally susceptible wildlife species (or family/orders) A single report on detection of bovine leukaemia virus (BLV) antibodies in one free-ranging European bison (Bison bonasus) from Poland has been published (Kita and Anusz, 1991) . Otherwise, under natural conditions, BLV has not been found in any wild ruminants like deer, llama, antelopes. Other species have been suspected but not confirmed as naturally susceptible species (e.g. capybara, rhesus monkeys, chimpanzees) (EFSA AHAW Panel, 2015) .
Parameter 2 -Naturally susceptible domestic species (or family/orders)
The following species are considered naturally susceptible among domestic species:
• Bos taurus (domestic cattle), • Bos indicus (zebu), • Bubalus bubalis (water buffalo) (EFSA AHAW Panel, 2015) , • Bos grunniens (yak) (Ma et al., 2016) .
Spill over to other domesticated ungulates may occur (primarily in BLV high prevalent areas). The species having been affected are:
• Ovis aries (domestic sheep) (Green et al., 1988; Pannwitz et al., 1988; Kunakov and Abakin, 1993; Nekoei et al., 2015) ,
• Vicugna pacos (Huacaya alpaca) (Lee et al., 2012) .
Parameter 3 -Experimentally susceptible wildlife species (or family/orders) No experimentally susceptible wildlife species are known.
Parameter 4 -Experimentally susceptible domestic species (or family/orders)
The following species have been subject to successful experimental infection:
• Ovis aries (domestic sheep), • Capra aegagrus hircus (domestic goat), • Oryctolagus cuniculus (common rabbit) (EFSA AHAW Panel, 2015) .
Reservoir animal species
Parameter 5 -Wild reservoir species (or family/orders) There are no wild reservoir species.
Parameter 6 -Domestic reservoir species (or family/orders)
The following domestic species are considered natural reservoir of the disease:
• Bos taurus (domestic cattle), • Other domesticated bovine animals depending on region: Bos indicus (zebu), Bubalus bubalis (water buffalo),
• Bos grunniens (mutus) (yak).
Article 7(a)(ii) The morbidity and mortality rates of the disease in animal populations
Morbidity
Parameter 1 -Prevalence/Incidence
The EBL-free Member States (MSs) or regions thereof are laid down in the newest version of Commission Decision 2003/467/EC 1 . It was recently amended by Commission Implementing Decision (EU) 2017/888 2 . Officially free MSs are now Belgium, the Czech Republic, Denmark, Germany, Estonia, Ireland, Spain, Cyprus, Latvia, Lithuania, Luxembourg, the Netherlands, Austria, Poland, Slovenia, Slovakia, Finland, Sweden, France (except Reunion Island), the United Kingdom, and in addition, some provinces in Italy, and Portugal.
On the other hand, the results of the surveillance up to 2015 are presented in the annual report 'Bovine and Swine Diseases -Situation 2015'. 3 The overall herd prevalence was 0.12% by serological test (827,000 bovine herds tested in European Union (EU)), and 0.01% by examination of bulk milk samples (84,361 bovine herds tested). The between-herd serological prevalence in MSs with seroprevalence > 0 is reported in Table 1 . Prevalence estimates of BLV infection in the USA, Argentina, Chile, Japan, and select areas of Canada, China and Iran are reported in Table 2 .
The between-herd prevalence of BLV in non-European countries are summarised in 135, 24.5.2017, p. 27-34. 3 https://ec.europa.eu/food/sites/food/files/animals/docs/la_bovine_final_report_2015.pdf Parameter 2 -Case-morbidity rate (% clinically diseased animals out of infected ones) Infected animals, after a latency that extends from a few months to several years, develop a polyclonal proliferation of B cells called persistent lymphocytosis in 30-50% of cases. Persistent lymphocytosis is usually stable for several years but it may also evolve to lymphoma, a malignant tumour of lymphoid tissue, which is the main clinical manifestation of BLV infection. Animals with persistent lymphocytosis have a higher probability of developing lymphoma, thus it is considered as a pre-tumour stage (EFSA AHAW Panel, 2015) .
Regarding lymphoma frequency, the development of lymphomas is a late manifestation of BLV infection, because lymphomas are recorded at the end of the productive life of animals (at slaughter, at death or euthanasia in the herd). The number of animals developing lymphomas is usually recorded per year in the population at risk (period prevalence), but more often it is recorded at slaughter during meat inspection as the prevalence of animals condemned due to lymphoma. The difficulty in assessing the lymphoma impact over time is that seldom both lymphoma incidence and prevalence of BLV infection are known (EFSA AHAW Panel, 2015) . In Europe before and in the early phases of eradication period, prevalence of 1% in dairy cows have been recorded for example in Germany, corresponding to 2-5% of adult cows developing disease. Similarly in Sweden, lymphomas were diagnosed in approximately 1% of slaughtered cows during the early 1960s from high-prevalence regions. In more recent times, in the USA the period prevalence in slaughtered cows 2005-2007 was Morovati et al. (2012) 0.8%, while in Canada prevalence in slaughter cattle in high BLV-prevalence region in the period 1999-2012 was 0.5% (EFSA AHAW Panel, 2015) . Due to the uncertainty in estimating the frequency of lymphomas due to BLV infection, in countries with modern dairy production systems and no control programme for EBL, the best estimate of the cumulative lymphoma incidence in BLV-infected cows is 1-2%, mostly in cattle older than 3-5 years. In high prevalence herds, the cumulative lymphoma incidence among dairy cows may reach 5%.
The morbidity and mortality due to EBL in the EU is currently negligible as a consequence of strict control measures applied since the 1990s. Since 2011, only 19 confirmed lymphoma cases have been reported from all MSs (European Commission, 2011a , 2015 .
Mortality
Parameter 3 -Case-fatality rate
The malignant tumoral form of BLV infection (lymphomas) invariably lead to death of the animal within months, thus with a case-fatality rate of 100% (EFSA AHAW Panel, 2015) .
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 -Report of zoonotic human cases (anywhere) BLV genome sequences have been found in breast cancer tissue, but no evidence has indicated an aetiological role of BLV in human disease (Buehring et al., 2001 (Buehring et al., , 2014 (Buehring et al., , 2015 Baltzell et al., 2009) . 
Environment
Parameter 4 -Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil, water, air) from the environment (scenarios: high and low T) BLV is associated to cells and viral particles are not excreted in free forms in the environment. Infected cells may survive for a limited time in blood or milk, they are sensitive to freezing and high temperatures and are readily inactivated by UV light, thereby losing the ability to replicate and transmit BLV. BLV-infected cultured cells heated to 60°C or higher for 1 min did not infect inoculated cells. In vitro at 4°C the BLV in cells survived in blood containing anticoagulant and BLV antibodies for at least 2 weeks. In blood without BLV antibodies, the virus survived at least for 4 weeks (EFSA AHAW Panel, 2015) .
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 -Types of routes of transmission from animal to animal (horizontal, vertical) Horizontal: Any mechanism able to transmit blood or infected lymphocytes between animals should be considered.
• Direct Contact with body excretions containing BLV-infected lymphocytes (e.g. saliva, milk) may result in infection of susceptible animals.
The risk of transmission of BLV via semen or embryos has been considered negligible, whereas natural mating with infected bulls may lead to transmission due to intense direct contact on mating.
• Indirect Iatrogenic transmission via use of blood-contaminated needles, instruments for tattooing or dehorning, contaminated gloves for rectal palpation is possible. The use of milking machines compared to manual milking has also been associated with BLV infection (EFSA AHAW Panel, 2015) .
Haematophagus insects (flies) may contribute to the spread of BLV within a herd by mechanically transferring lymphocytes via biting. Horse flies (Tabanus spp.) may have greater potential to transmit BLV within herds. 
Speed of transmission
Parameter 3 -Incidence between animals and, when relevant, between animals and humans The rate of transmission between animals is dependent on the within herd prevalence in specific herds. Herd management factors (like housing system, calving management) may impact the spread of the virus within herd (Table 3 ).
The incidence rate (determined by seroconversion and/or detection of provirus) varies in different age groups. Perinatal transmission to newborn calves is observed in a minority of births (3-11.5%) from infected dams. The incidence increases around first lactation (EFSA AHAW Panel, 2015). (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) 20-34% 12-18% 9.5-18.3% 2.1-5.5% Kaja et al. (1984) Australia, dairy herd 42% 24% Dimmock et al. (1991) Italy, 9 dairy herds longitudinal study (1976) (1977) (1978) (1979) (1980) 11.0-11.7% 3.9% Rutili et al. (1982) Estonia, dairy cattle national population (1989) (1990) (1991) (1992) Parameter 2 -Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
In countries where EBL is still present, the epidemiological occurrence can be considered endemic.
Risk of introduction
Risk of introduction is estimated at EU level. As BLV is present in the EU, this is not assessed here. 
Diagnostic tools
See Section 3.1.4.1.
Control tools
Parameter 2 -Existence of control tools (Table 5 ) The MSs that are not officially free from BLV infection are Bulgaria, Greece, Croatia, Hungary, Italy, France, Lithuania, Latvia, Malta, Portugal and Romania (See Sections 3.1.1.2 and 3.1.1.7).
The loss of production due to the disease Parameter 2 -Proportion of production losses (%) by epidemic/endemic situation On EU level, the losses can be considered negligible due to low prevalence. On regional and herd level the losses may be significant.
Tumours: As explained in Section 3.1.1.2, the losses due to EBL lymphoma in the EU is currently negligible (less than 20 cases since 2011), as a consequence of strict control measures applied since the 1990s. In countries where no control programme is in place and with modern dairy production systems, the cumulative lymphoma incidence among dairy cows may reach 5% (EFSA AHAW Panel, 2015) .
Milk production: Since the impact of BLV infection on reduction of milk yield is difficult to assess from observational studies because of the influence of age, herd size, lactation number and genetic potential, the selection of study design and methods to consider possible confounders is important. The results of the systematic review conducted by EFSA in 2015 are summarised in Table 6 .
Reproduction: The impact is not known and controversial. An increased calving interval in BLVpositive cows -up to 2 weeks, but there are studies where significant impact of BLV infection was not identified (EFSA AHAW Panel, 2015) .
Mastitis: The impact on udder health is also controversial, while some studies reported an increased level of somatic cells in milk in BLV-infected cows, in particular for cows with persistent lymphocytosis, but other studies did not detect significant differences between BLV-positive and -negative animals.
The clinical significance of these findings remains inconclusive (EFSA AHAW Panel, 2015) . Cow longevity: the impact on cow longevity is summarised in Table 7 .
Article 7(b)(ii) The impact of the disease on human health
The impact on human health is estimated only for zoonotic diseases. There is no scientific grounds to classify EBL as a zoonotic disease, thus this aspect is not relevant.
Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 -Severity of clinical signs at case level and related level and duration of impairment The development of tumours is accompanied by chronic ill health, progressive loss of body condition, weakness, anaemia and anorexia, attributable to infiltration of tumours into various internal organs. Tumours are not likely to be detected until they cause conspicuous pathophysiological manifestations. The animal welfare consequences in terms of duration and severity may vary according to the location and magnitude of the spread of tumours in organs, e.g. heart, kidneys, lungs, central nervous system or gastrointestinal system. Overall, animals will suffer when tumours have progressed beyond early stages. It is also likely that BLV-infected cattle suffer considerably during the last months of their lives due to immunosuppression. In addition, the EBL has significant impact on cow longevity being a cause of early culling of affected animals. Due to slow development of the disease, the increased mortality due to the disease occurs in older age classes. Therefore, the potential of the infection to cause increased mortality in wild populations is not known, it may be most likely minor.
Environment
Parameter 3 -Capacity of the pathogen to persist in the environment and cause mortality in wildlife
The capacity of the BLV to persist in the environment is very low (see parameter 3, Section 3.1.1.5). The risk of spreading of the infection to wildlife populations through environmental contamination can be considered negligible. The difference in the probability of culling or death between the BLV positive and negative cohorts gradually increased, from 13.4% at the second lactation to 26.2% at the seventh lactation Nekouei et al. (2016a) 3,849 Holstein dairy cows in 112 herds in Michigan, US BLV-positive cows were 23% more likely than their BLV-negative herd mates to die or be culled Bartlett et al. (2013) 4200 dairy cows in 104 Michigan dairy herds, US Herds with higher rates of BLV had significantly lower longevity Erskine et al. (2012) Sweden, national dairy cattle population Significantly higher rate of culling in BLV infected herds v. non infected Emanuelson et al. (1992) AHL assessment on enzootic bovine leukosis (EBL) Internationally recognised diagnostic tools according to OIE are listed in Table 8 .
Effectiveness
Parameter 2 -Se and Sp of diagnostic test
Limited information exist on the diagnostic accuracy of available diagnostic tests. Most test evaluations have compared enzyme-linked immunosorbent assay (ELISA) and agar gel immunodiffusion test (AGID) and found the former to be equally or more sensitive. Relative to infection, Klintevall et al. (1991) reported that the ELISA test is capable of detecting herds with withinherd prevalences of 4-5%. OJ 121, 29.7.1964 OJ 121, 29.7. , p. 1977 OJ 121, 29.7. -2012 (1): Not OIE certified method for diagnosis of EBL. Histological examination supports the diagnosis of malignant tumours but is not able to distinguish between sporadic lymphomas and those induced by BLV.
Feasibility
Parameter 3 -Type of sample matrix to be tested (blood, tissue, etc.) See Parameter 1.
Article 7(d)(ii) Vaccination
There are no vaccines available.
Article 7(d)(iii) Medical treatments
There is no medical treatment available.
Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 -Available biosecurity measures BLV is almost exclusively transmitted between herds by movement of infected live cattle. Iatrogenic transmission contributes mainly to the spread within herd although between herds transmission cannot be completely excluded via use of blood-contaminated needles, instruments for tattooing or dehorning as well as rectal palpation using contaminated gloves.
The biosecurity measures directed to eliminate these routes of transmission are:
• Introduction of animals from certified BLV infection free herds • Avoiding contacts with infected animals (e.g. common pastures, during transportation, mating)
• Avoiding iatrogenic introduction:
-Use of disposable needles or needles sterilised by boiling -Use of cleaned and disinfected equipment to assist calving, for ear tattooing, feeding and medication etc. 4 one of the conditions for officially EBL-free herd to retain its free status is, that (ii) 'any animals introduced into the herd come from an officially EBL-free herd'.
Thus, the movement restrictions on animals from herds not officially free are partial as they can be moved to other herds of the same health status.
Pursuant to Article 6 Point 3, animals from herds not officially EBL free are not allowed to move to slaughter in another MS.
Effectiveness
Parameter 2 -Effectiveness of restriction of animal movement in preventing the between farm spread BLV is almost exclusively transmitted between herds by movement of infected live cattle. Movement restrictions have proved to be an effective tool in preventing the spread between herds (EFSA AHAW Panel, 2015).
Feasibility
Parameter 3 -Feasibility of restriction of animal movement
The movement restrictions are applied at herd level and these restrictions allow limited movement of animals within the country to herds of the same health status as well as to slaughter without restrictions. Thus, the movement restrictions do not cause severe consequences to the normal farm functioning. The impact of these restrictions to farm economy is related to restricted possibilities to sell live animals for breeding (EFSA AHAW Panel, 2015) .
Article 7(d)(vi) Killing of animals
Availability
Parameter 1 -Available methods for killing animal For the eradication of the disease, the selective slaughter of infected animals ('test and slaughter' strategy) is applied. Culled animals undergo normal slaughter at abattoirs.
Effectiveness
Parameter 2 -Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping spread of the disease Prompt culling of infected animals from herds has proven to be the most effective disease eradication measure (EFSA AHAW Panel, 2015).
Feasibility
Parameter 3 -Feasibility of killing animals Culled animals undergo normal slaughter at abattoirs, thus the process of killing of animals does not imply any specific arrangements and doesn't have any extra economic or animal welfare consequences.
The possible impact of killing of infected animals on farm economy is related to loss of animals before the end of their productive life. These losses can be considered minor compared to the positive effects of the disease freedom status on herd health and welfare as well as farm economy.
Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Parameter 1 -Available disposal option Animals undergo normal slaughter at abattoirs and their by-products are disposed according to general rules and regulations for slaughterhouses. 5, 6 The disposal of by-products in slaughterhouse facilities guarantees the destruction of the virus without environmental consequences. If parts of the carcasses showing signs of the disease are not fit for human consumption, those and the blood of such animals have to be categorised as animal-by products of Category 2 which often implies higher disposal costs and certain ABP uses are not allowed (e.g. pet food).
3.1.5. Article 7(e) The impact of disease prevention and control measures 3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the economy as a whole
Parameter 1 -Cost of control (e.g. treatment/vaccine, biosecurity)
The cost of control measures depend on type of measures applied in a farm. Control by improved biosecurity does not cause significant additional expenditures for farmers as biosecurity measures applied are part of good farming practice and general hygienic measures.
If control measures include testing of animals and regrouping/separating infected animals, then costs are increasing accordingly.
In US the mean annual cost of a test-and-manage control programme was estimated to be 1,765 dollars per herd. The cost of control varied with herd size (Rhodes et al., 2003) .
Parameter 2 -Cost of eradication (culling, compensation)
The main costs of the eradication programmes have been related to regular testing of cattle herds, and compensation for slaughtered infected animals. Some additional costs may be associated with regrouping and separation of infected animals in high prevalence herds as well as with improvement of biosecurity measures.
Between 2007 and 2011, the total cost incurred by the Health Service of Lazio Region (Italy) for the eradication of EBL was estimated in 6,134,694 EUR, of those about 2.5 million were the cost of the veterinarians labour, 8,864 for the transport, 23,908 for disposal and compensation for culled animals (Caminiti et al., 2016) .
In 1993 . The EU contribution for EBL eradication programmes was provided to seven MSs (listed in Table 9 ) during the period 2005-2010. The estimated 6-year average annual costs (excluding sampling costs) were in all MSs less than €15 per herd or €11 or less per 10 cows in a national population, with the exception of Malta, where more funds were needed for compensations for culled animals due to higher BLV prevalence compared to the other six countries. In other MSs, the costs are mainly related to testing of cattle. The average annual expenditures in Malta (€1,019 per herd; €426 per 10 cows) reflect the extent of costs during the first phases of eradication, when significant proportion of animals has to be culled. Parameter 3 -Cost of surveillance and monitoring
In regions free of EBL, continued surveillance is based on a combination of serological testing of adult animals and identification of tumours at slaughter (EFSA AHAW Panel, 2015) .
The identification of tumours at slaughter is part of regular carcass inspection and the additional costs are related to laboratory investigation of suspect tumours (histology and PCR).
The monitoring of BLV free dairy herds is based on regular testing of individual or pooled (bulk) milk samples for BLV antibodies by ELISA test from all or representative sample of herds depending of the stage of the control programme (eradication or maintaining of the free status) (EFSA AHAW Panel, 2015) .
The surveillance costs comprise of labour costs of managers of the programme as well as sample collectors, the cost of materials used for the blood and milk sampling, transportation costs related to farm visits and the delivery costs of samples and laboratory costs.
In Switzerland, the unit price per tested sample including labour, materials and general laboratory charges were estimated to be for a blood serum ELISA at 21.70 CHF and for bulk tank milk ELISA at 25 CHF including analysis of samples for BLV and Bovine Herpes Virus 1 antibodies (Reber et al., 2012) .
Data provided in Table 9 largely reflect the costs of surveillance (except for Malta) in EU Member States as the main expenditures have been related to testing of cattle herds.
Parameter 4 -Trade loss (bans, embargoes, sanctions) by animal product Pursuant to Council Directive 64/432/EEC, Annex D, Chapter 1B, one of the conditions for officially EBL free herd to retain its free status is, that (ii) 'any animals introduced into the herd come from an officially enzootic-bovine-leukosis-free herd'.
Thus, the movement restrictions to animals from not officially free herds are partial as they can be moved to other herd of the same health status.
Pursuant to Article 6 Point 3, animals from not officially EBL free herds are not allowed to move to slaughter in another member state.
According to Article 11.8.5 of the Chapter 11.8 of the OIE Terrestrial Animal Health Code, the imported animals should be free of BLV infection. The disease freedom of the animal has to be certified by the veterinary service of the exporting country (OIE, 2016b).
Parameter 5 -Importance of the disease for the affected sector (% loss or € lost compared to business amount of the sector) Due to the successful eradication of EBL, the impact of the disease on agricultural production in MS is currently negligible. This statement is also valid for MS with low prevalence of infection but not yet officially free. However, the losses in affected herds are proportional to the within herd prevalence of the infection (EFSA AHAW Panel, 2015) .
In United States, the estimated loss to the dairy industry in 1993 due to BLV caused milk and fat yields decline associated with persistent lymphocytosis (PL) only was more than $42 million annually in the situation where at least 50% of Holstein herds were infected with BLV and within infected herds 70% of animals were assumed to be infected and 20% of the infected animals develop PL (Da et al., 1993) .
The loss of productivity in BLV positive dairy herds in USA resulted in a $285 million loss of economic surplus for producers and $240 million for consumers making a total of $525 million (Ott et al., 2003) .
On herd level, the estimated mean cost to the producer per lymphoma case was 412 dollars and the mean annual cost of subclinical infection at a 50% prevalence of infection was 6,406 dollars per 100 milking cows in 2003 (Rhodes et al., 2003) .
Article 7(e)(ii) The societal acceptance of disease prevention and control measures
There is no evidence of any societal non-acceptance towards EBL control programme. The possible zoonotic potential of the BLV has been of some concern and has got some attention of general public in early years after discovery of the virus and more recently in connection with reports on discovery of the virus in breast tumours of humans. 
Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL about enzootic bovine leukosis (Table 10) 
Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was achieved in form of tables (Tables 11 and 12 ). The proportion of Y, N or na answers are reported, followed by the list of different supporting views for each answer.
Reasoning supporting the judgement Supporting Yes:
• In endemic areas within the EU, seroprevalence ranges from 0.01% to 12% (2015), 0% to 1-2% of BLV-infected animals can develop lymphomas. Furthermore, there is evidence that BLV-infected herds register a reduction in milk yield.
Supporting No:
• The probability to develop lymphomas over the lifespan of the animals is low.
• On EU level, the losses can be considered negligible due to low prevalence following decades of control programmes. On regional and herd level, the losses may be significant.
• In herds with test-positive cows compared to herds with no test-positive cows, a reduction in milk yield of 3% has been observed (218 kg/cow). Over the entire study lifespan, the testpositive herd produced 11,000 kg/cow less milk compared to the test-negative. In MSs currently BLV-free and where dairy production is important, such as Denmark or Ireland, these losses would cause a significant negative economic impact.
• EBL has a significant impact on milk yield (Table 6 ) and longevity (Table 7) , and can be a cause of early culling of affected animals (EFSA AHAW Panel, 2015) . At present, there may be limited impact of the disease in the Union due to a long-term eradication programme, but if disease barriers are removed, the prevalence would be expected to increase and could thus cause significant negative effects in the Union.
• In endemic situations, 1-2% of BLV-infected cattle develop lymphosarcoma, whereas in herds with higher infection prevalence, up to 5%. Lymphosarcoma is one of the main causes of condemnation of adult dairy cows at slaughter. However, lymphoma is rarely seen in animals younger than 2 years of age and is most common in the 4-to 8-year-old age group. Therefore, most of the affected animals, especially in the dairy sector, will be slaughtered before the development of lymphoma or before symptoms are evident. In these animals, lymphomas are generally found as an incidental post-mortem finding. 
The disease causes or could cause a significant negative economic impact affecting agriculture or aquaculture production in the Union NC 62 38 0 NC: non-consensus; number of judges: 8.
• Experiences from US and Canada should be extrapolated to Europe with care due to important differences in farm size and structure. Prevalence is generally low and consequences are therefore not significant.
Outcome of the assessment of EBL according to criteria of Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article 5 if it fulfils all criteria of the first set from A(i) to A(v) and at least one of the second set of criteria from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is considered fulfilled when the outcome is 'Yes'. According to the results shown in Table 10 , EBL complies with all criteria of the first set, but not with at least one criterion of the second set because the assessment is inconclusive on compliance with criteria 5 B(i) and 5 B(iii). Therefore, it is inconclusive whether EBL can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL.
Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to categories as in Article 9 of the AHL about EBL (Tables 13-17 ). The expert judgement was based on ICBA approach described in detail in the opinion on the methodology. Experts have been provided with information of the disease fact-sheet mapped into Article 9 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or 'na' judgement on each criterion of Article 9, and the reasoning supporting their judgement. The minimum number of judges in the judgement was eight. The expert judgement was conducted as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017). The disease may result in high morbidity and significant mortality rates N At least one criterion to be met by the disease: In addition to the criteria set out above at points 1-2.4, the disease needs to fulfil at least one of the following criteria 3
The disease has a zoonotic potential with significant consequences on public health, including epidemic or pandemic potential OR possible significant threats to food safety
The disease has a significant impact on the economy of the Union, causing substantial costs, mainly related to its direct impact on the health and productivity of animals The disease may result in high morbidity with in general low mortality N At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1-2.4, the disease needs to fulfil at least one of the following criteria 3
The disease has a zoonotic potential with significant consequences on public health, including epidemic potential OR possible significant threats to food safety
The disease has a significant impact on the economy of the Union, causing substantial costs, mainly related to its direct impact on the health and productivity of animals The disease usually does not result in high morbidity and has negligible or no mortality AND often the most observed effect of the disease is production loss Y At least one criterion to be met by the disease:
The disease has a zoonotic potential with significant consequences on public health, or possible significant threats to food safety
The disease has a significant impact on the economy of parts of the Union, mainly related to its direct impact on certain types of animal production systems Table 17 : Outcome of the expert judgement related to the criteria of Section 5 of Annex IV (category E of Article 9) for enzootic bovine leukosis Diseases in category E need to fulfil criteria of Sections 1, 2 or 3 of Annex IV of AHL and/or the following:
Final outcome E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare, human health, the economy, society or the environment (If a disease fulfils the criteria as in Article 5, thus being eligible to be listed, consequently category E would apply.)
NC
Colour code: yellow = no consensus (NC).
Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 18 and  19 ). The proportion of Y, N or 'na' answers are reported, followed by the list of different supporting views for each answer.
Reasoning supporting the judgement Supporting Yes for 1 (cat. A):
• The disease is present in a limited part of the EU territory or only in exceptional cases as most MSs (18-28) (i.e. more than several) are EBL-free including the MSs with an important bovine population.
Supporting Yes for 1 (cat. B):
• Based on the map distribution of the disease in the EU, EBL is present in a limited part of the EU (mostly in the Balkans). Therefore, endemic infection is present in a very limited part of the EU cattle population, whereas several MSs or zones of the Union are free of the disease.
• The prevalence of the disease can be significant, e.g. 60% (herd prevalence) in a Canadian study from 2002, and the impact as well.
• The animal welfare consequences in terms of duration and severity may vary according to the location and magnitude of the spread of tumours in organs, e.g. heart, kidneys, lungs, central nervous system or gastrointestinal system. Overall, animals will suffer when tumours have progressed beyond an early stage.
• In endemic countries, 1-2% of BLV-infected animals develop lymphomas (EFSA AHAW Panel, 2015) and in high prevalence herds the cumulative lymphoma incidence among dairy cows may reach 5%. In terms of welfare, these are large numbers of animals.
• Experiences from the US and Canada should be extrapolated to Europe with care due to important differences in farm size and structure. • Not a large number of animals are affected by the disease, and only the development of tumours in the last stages is a source of pain. The case-morbidity is overall negligible, even in animals that have lived long enough to show tumours.
3.3.2. Outcome of the assessment of criteria in Annex IV for EBL for the purpose of categorisation as in Article 9 of the AHL As from the legal text of the AHL, a disease is considered fitting in a certain category (A, B, C, D or E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union intervention as laid down in Article 5(3) and fulfils all criteria of the first set from 1 to 2.4 and at least one of the second set of criteria from 3 to 5(d) as shown in Tables 13-17 . According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is considered fulfilled when the outcome is 'Yes'. With respect to different type of impact where the assessment is divided into current and potential impact, a criterion will be considered fulfilled if at least one of the two outcomes is 'Y' and, in case of no 'Y', the assessment is inconclusive if at least one outcome is 'NC'.
A description of the outcome of the assessment of criteria in Annex IV for EBL for the purpose of categorisation as in Article 9 of the AHL is presented in Table 20 .
According to the assessment here performed, EBL complies with the following criteria of the Sections 1 to 5 of Annex IV of the AHL for the application of the disease prevention and control rules referred to in points (a) to (e) of Article 9(1): 1) To be assigned to category A, a disease needs to comply with all criteria of the first set (1, 2.1-2.4) and according to the assessment EBL complies with criteria 2.2 and 2.3, but not with criteria 2.1 and 2.4 and the assessment is inconclusive on compliance with criterion 1. To be eligible for category A, a disease needs to comply additionally with one of the criteria of the second set (3, 4, 5a-d) and EBL does not comply with any of the criteria and the assessment is inconclusive on compliance with criterion 5b. 2) To be assigned to category B, a disease needs to comply with all criteria of the first set (1, 2.1-2.4) and according to the assessment EBL complies with criteria 2.2 and 2.3, but not with criteria 2.1 and 2.4 and the assessment is inconclusive on compliance with criterion 1. To be eligible for category B, a disease needs to comply additionally with one of the criteria of the second set (3, 4, 5a-d) and EBL does not comply with any of the criteria and the assessment is inconclusive on compliance with criterion 5b. 3) To be assigned to category C, a disease needs to comply with all criteria of the first set (1, 2.1-2.4) and according to the assessment EBL complies with criteria 2.2, 2.3 and 2.4, but www.efsa.europa.eu/efsajournalnot with 1 and 2.1. To be eligible for category C, a disease needs to comply additionally with one of the criteria of the second set (3, 4, 5a-d) and EBL does not comply with any of the criteria and the assessment is inconclusive on compliance with criterion 5b. 4) To be assigned to category D, a disease needs to comply with criteria of Section 1, 2, 3 or 5 of Annex IV of the AHL, whose assessment performed is inconclusive for EBL, and with the specific criterion D of Section 4, with which EBL complies. 5) To be assigned to category E, a disease needs to comply with criteria of Section 1, 2 or 3 of Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating to animal health, animal welfare, human health, the economy, society or the environment. The latter is applicable if a disease fulfils the criteria as in Article 5 and the assessment here performed for EBL is inconclusive on compliance with the criteria as in Article 5.
Assessment of Article 8
• According to the assessment here performed, it is inconclusive whether EBL can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL. Eligibility of listing EBL is dependent on a decision on criteria 5 B(i) and 5 B(iii).
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, since it is inconclusive whether EBL can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL, then also the assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of categorisation of diseases in accordance with Article 9 of the AHL is inconclusive for the assignment to categories (d) and (e) of Article 9 of the AHL.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list of animal species that should be considered candidates for listing in accordance with Article 8 of the AHL.
• According to the assessment here performed, since it is inconclusive whether EBL can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL, then it is also inconclusive which animal species can be considered to be listed for EBL according to Article 8(3) of the AHL.
